双新月征作为慢性硬膜下血肿钻孔术后复发的预测因素
该研究回顾性分析2012年4月至2017年3月接受单孔钻孔术的278例慢性硬膜下血肿患者,评估术后CT双新月征与血肿复发的关系。277例患者中50例(18.1%)在术后3个月内复发,多因素分析显示双新月征(OR 3.36)、术后残余血肿量大(OR 2.88)、抗凝治疗(OR 3.03)和双侧血肿(OR 3.57)为复发的独立预测因素。作者主张临床医生应密切监测术后双新月征及后续血肿复发。
要点
- 双新月征是术后CT上残余血肿与低密度液性间隙构成的双层征象。
- 104个存在双新月征的大脑半球中32个在术后3个月内复发血肿。
- 双新月征、术后残余血肿量大、抗凝治疗和双侧血肿为复发的独立预测因素。
核心结论
- 术后7天内检出双新月征是慢性硬膜下血肿复发的独立预测因素,作者主张临床医生应密切监测术后双新月征及后续血肿复发。
研究设计与样本
- 回顾性分析2012年4月至2017年3月接受单孔钻孔术的278例连续慢性硬膜下血肿患者,最终277例(320个大脑半球)纳入分析。
主要发现
- 277例患者中50例(18.1%)在术后3个月内复发慢性硬膜下血肿。
- 104个存在双新月征的大脑半球中32个在术后3个月内复发。
- 多因素logistic回归显示双新月征(OR 3.36,95%CI 1.72-6.57,p < 0.001)、术后残余血肿量大(OR 2.88,95%CI 1.24-6.71,p = 0.014)、抗凝治疗(OR 3.03,95%CI 1.02-9.01,p = 0.046)和双侧血肿(OR 3.57,95%CI 1.79-7.13,p < 0.001)为复发的显著独立预测因素。
关键数值与推荐
- 双新月征定义为术后CT上由残余血肿构成的浅层和脑表面与残余血肿之间低密度间隙构成的深层组成的双层征象。
临床怎么用
- 作者主张临床医生应密切监测术后双新月征及后续慢性硬膜下血肿复发。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Subdural hygroma has been reported as a causative factor in the development of a chronic subdural hematoma (CSDH) following a head trauma and/or neurosurgical procedure. In some CSDH cases, the presence of a 2-layered space delineated by the same or similar density of CSF surrounded by a superficial, residual hematoma is seen on CT imaging after evacuation of the hematoma. The aims of the present study were to test the hypothesis that the double-crescent sign (DCS), a unique imaging finding described here, is associated with the postoperative recurrence of CSDH, and to investigate other factors that are related to CSDH recurrence. METHODS: The authors retrospectively analyzed data from 278 consecutive patients who underwent single burr-hole surgery for CSDH between April 2012 and March 2017. The DCS was defined as a postoperative CT finding, characterized by the following 2 layers: a superficial layer demonstrating residual hematoma after evacuation of the CSDH, and a deep layer between the brain's surface and the residual hematoma, depicted as a low-density space. Correlation of the recurrence of CSDH with the DCS was evaluated by multivariate logistic regression modeling. The authors also investigated other classic predictive factors including age, sex, past history of head injury, hematoma laterality, anticoagulant and antiplatelet therapy administration, preoperative hematoma volume, postoperative residual hematoma volume, and postoperative brain reexpansion rate. RESULTS: A total of 277 patients (320 hemispheres) were reviewed. Fifty (18.1%) of the 277 patients experienced recurrence of CSDH within 3 months of surgery. CSDH recurred within 3 months of surgery in 32 of the 104 hemispheres with a positive DCS. Multivariate logistic analyses revealed that the presence of the DCS (OR 3.36, 95% CI 1.72-6.57, p < 0.001), large postoperative residual hematoma volume (OR 2.88, 95% CI 1.24-6.71, p = 0.014), anticoagulant therapy (OR 3.03, 95% CI 1.02-9.01, p = 0.046), and bilateral hematoma (OR 3.57, 95% CI 1.79-7.13, p < 0.001) were significant, independent predictors of CSDH recurrence. CONCLUSIONS: In this study, the authors report that detection of the DCS within 7 days of surgery is an independent predictive factor for CSDH recurrence. They therefore advocate that clinicians should carefully monitor patients for postoperative DCS and subsequent CSDH recurrence.
引用
- Miki K, Abe H, Morishita T, et al. Double-crescent sign as a predictor of chronic subdural hematoma recurrence following burr-hole surgery. J Neurosurg. 2019. PMID: 30611142. doi:10.3171/2018.8.JNS18805
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。